RecruitingNCT06371261

Pathogenicity of Species of the Achromobacter Genus in Patients From Reunion Island With Cystic Fibrosis

Pathogenicity of Species of the Achromobacter Genus in Patients With Cystic Fibrosis: a Prospective Multicentre Exploratory Study of a Cohort in Réunion Island.


Sponsor

Centre Hospitalier Universitaire de la Réunion

Enrollment

35 participants

Start Date

Mar 12, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The pathogenicity of Achromobacter bacteria is not yet well established, but studies show a decline in respiratory function and an increase in mortality associated with chronic colonisation, making it possible to classify the Achromobacter genus as an emerging pathogen in cystic fibrosis. It is possible that certain species or clones are more virulent or resistant, requiring the adaptation of measures to prevent cross-transmission in the centres concerned. However, until now, the identification of Achromobacter species has involved the use of molecular biology techniques that are not routinely applicable in diagnostic laboratories, limiting studies and the collection of epidemiological data. Recently, a database using MALDI-TOF mass spectrometry has been built for rapid and accurate species identification. In view of the local epidemiology and the current lack of data, it would be necessary and interesting to use this tool to study a cohort of cystic fibrosis patients in Réunion island (North and South sites) to see whether one species has a greater clinical impact than another (pathogenicity), and/or is more responsible for chronic colonisation.


Eligibility

Inclusion Criteria4

  • Minor or major cystic fibrosis patients
  • Patients with at least one sputum cytobacteriological test positive for Achromobacter spp. during the inclusion period.
  • Patients living in La Réunion island.
  • Patients for whom a non-opposition was obtained orally (if applicable from both one of the child's legal guardians and the child him/herself)

Exclusion Criteria2

  • Patients without cystic fibrosis.
  • Patients with cystic fibrosis but no Achromobacter-positive ECBC during the study inclusion period

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBiological analyses

A cytobacteriological examination of the sputum will be carried out and sent to the microbiology laboratory at the University Hospital of La Réunion. The micro-organisms will be quantified. The micro-organisms, and more specifically bacteria of the Achromobacter genus, will be identified by MALDI-TOF mass spectrometry using the published database (Garrigos et al.2021).


Locations(2)

CHU la Réunion North

Saint-Denis, Reunion

CHU la Réunion South

Saint-Pierre, Reunion

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06371261


Related Trials